| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2658d45a8e9c71b9598e2bf83242bab3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate |
2020-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7f75e3a59c59f6aa299c588c7ff0a7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f62184defd64d5b32a9bb57a3094b8a9 |
| publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021050563-A1 |
| titleOfInvention |
Antibody treatment for lesional tissue of hidradenitis suppurativa |
| abstract |
Provided are methods for treating Hidradenitis Suppurativa (HS). The methods include administering to an HS patient an IL-17 receptor agonist. A representative IL-17 receptor agonist is brodalumab. Weekly brodalumab dosing improves HS in patients with draining tunnels. In embodiments, the IL-17 receptor agonist comprises an IL-17 receptor binding partner that specifically binds to human IL- 17 receptor A, and inhibits the binding of EL-17A to said IL- 17 receptor A. |
| priorityDate |
2019-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |